Altos Labs, Retro Biosciences, and Loyal are the three most closely watched companies racing to turn anti-aging research into an actual product, and the honest surprise in comparing them is that the most heavily funded company has the least to show clinically, while the company furthest from Silicon Valley headlines — one developing drugs for dogs rather than humans — is genuinely the closest of the three to real regulatory approval. Funding size and press coverage turn out to be a poor proxy for how close any of this actually is to reaching patients, or pets.
Altos Labs: Most Funded, Least Clinically Advanced
Altos Labs holds the title of most heavily funded biotech startup in history, having raised roughly $3 billion in a single Series A round backed by Jeff Bezos, Yuri Milner, and Arch Venture Partners, among others. The company's scientific bet is cellular reprogramming — using Yamanaka factors to partially reset adult cells to a more youthful state — pursued as a disease-agnostic strategy rather than targeting one specific condition. Altos recruited roughly half of the world's leading reprogramming scientists in 2023 with highly competitive compensation, and in 2024 published a landmark study showing partial reprogramming extended lifespan and improved health markers in mice. In May 2026, the company acquired Dorian Therapeutics to expand into senescent-cell-targeting therapies. What Altos still doesn't have, as of 2026, is any human clinical trial data, regulatory filing, or revenue — despite persistent rumors the company is gearing up for its first human trials.
Retro Biosciences: The AI-Powered Challenger Already in Human Trials
Retro Biosciences, backed by OpenAI CEO Sam Altman, has moved further and faster on the clinical side than its better-known rival. The company pursues multiple mechanisms in parallel — cellular reprogramming, autophagy enhancement, plasma therapeutics, and cell replacement approaches including microglia replacement for the brain — and partnered with OpenAI in early 2025 to build an AI model specifically for designing proteins capable of repairing aging cells. Retro's first human clinical trial began in December 2025, testing a pill designed to help clear protein aggregates linked to Alzheimer's disease. As of May 2026, CEO Joe Betts-LaCroix reported the trial was "going super good," with no dose-limiting toxicities observed, and early data was expected around August 2026. The same month, Retro raised additional funding at a $1.8 billion valuation — smaller than Altos's headline figure, but attached to an actual human trial already underway rather than a research program still building toward one.
Loyal: Skipping the Human Regulatory Maze by Starting With Dogs
Loyal takes the most pragmatic approach of the three, and arguably the most clinically advanced one, by deliberately not targeting humans first. The company is developing longevity drugs for dogs through the FDA's Minor Use and Minor Species (MUMS) pathway, a faster regulatory route than standard human drug approval, with the explicit strategy of using dog data as a stepping stone toward eventual human applications. Its lead candidate, LOY-001, an injectable for large- and giant-breed dogs that reduces the growth hormone IGF-1, received FDA acceptance of its Reasonable Expectation of Effectiveness (RXE) — one of three required milestones for conditional approval — back in November 2023. A second candidate, LOY-002, a daily pill for senior dogs, has gone even further: it cleared RXE in February 2025 and Target Animal Safety (TAS) in January 2026, satisfying two of the three requirements for conditional approval, with only manufacturing and controls data still pending. Loyal's STAY study, the largest veterinary clinical trial in history, has enrolled roughly 1,300 senior dogs across 70 U.S. veterinary clinics. The company has publicly discussed pricing in the $40 to $90 per month range and anticipates conditional approval and market availability sometime in 2026, pending completion of the remaining manufacturing and safety requirements.
So Who's Actually Closest to a Real Product?
By the metric that matters most — proximity to an actual approved, sellable product — Loyal is ahead of both far-better-funded human-focused competitors, simply by choosing a regulatory pathway built for a narrower, faster win. Retro Biosciences is the furthest along on the human side specifically, with a live clinical trial and data due within months. Altos Labs remains the best-funded and most scientifically prestigious of the three, but as of 2026 it's also the one with the least to show in terms of actual clinical progress, a reminder that capital and talent don't automatically compress a decade-plus biotech development timeline.
Head-to-Head Comparison
| Company | Core approach | Funding | Clinical status (2026) |
|---|---|---|---|
| Altos Labs | Cellular reprogramming (Yamanaka factors), disease-agnostic | ~$3 billion Series A | No human trials yet; 2024 mouse lifespan study published |
| Retro Biosciences | Reprogramming, autophagy, plasma therapeutics, cell replacement | $1.8 billion valuation (May 2026) | First human trial underway since December 2025; data expected August 2026 |
| Loyal | Longevity drugs for dogs via FDA MUMS pathway | Smallest of the three, multiple funding rounds | LOY-002 has cleared 2 of 3 conditional approval milestones; targeting 2026 market entry |
Frequently Asked Questions
Has any longevity biotech company actually gotten a drug approved?
Not yet for humans. Altos Labs and Retro Biosciences have no approved human drugs. Loyal is the furthest along toward any approval, with its dog longevity drug LOY-002 having cleared two of three FDA milestones required for conditional approval as of early 2026.
Why is a dog drug company considered ahead of billion-dollar human longevity startups?
Loyal uses the FDA's Minor Use and Minor Species pathway, a faster regulatory route designed for animal drugs, letting it reach late-stage regulatory milestones years before human-focused competitors, who face a much longer and more rigorous approval process.
Does Altos Labs have any human clinical trial data?
No, as of 2026. Despite raising roughly $3 billion and recruiting many leading reprogramming scientists, Altos Labs has published only preclinical results, including a 2024 mouse lifespan study, with no human trials or regulatory filings publicly confirmed yet.
What is Retro Biosciences' first human trial actually testing?
A pill designed to help clear protein aggregates linked to Alzheimer's disease, part of the company's broader approach to reversing age-related cellular damage. The trial began in December 2025, and the company reported no dose-limiting toxicities as of May 2026.